These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37558531)

  • 1. Clinical Efficacy of Retreatment With Venetoclax-Based Therapy in Relapsed-Refractory t(11;14) Multiple Myeloma.
    Dima D; Orland M; Ullah F; Anwer F; Mazzoni S; Raza S; Chaulagain CP; Samaras C; Valent J; Williams L; Khouri J
    Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):857-860. PubMed ID: 37558531
    [No Abstract]   [Full Text] [Related]  

  • 2. Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.
    Boccon-Gibod C; Talbot A; Le Bras F; Frenzel L; Royer B; Harel S; Lombion N; Belhadj K; Cuccuini W; Arnulf B
    Br J Haematol; 2020 May; 189(3):e73-e76. PubMed ID: 32012229
    [No Abstract]   [Full Text] [Related]  

  • 3. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
    Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
    Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
    Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
    J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.
    Abuelgasim KA; Alherz N; Alhejazi A; Damlaj M
    J Med Case Rep; 2020 Apr; 14(1):54. PubMed ID: 32321588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
    Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
    Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma.
    Kambhampati S; Galligan D; Huang CY; Wong S; Wolf J; Martin T; Shah N
    Leuk Lymphoma; 2020 May; 61(5):1211-1219. PubMed ID: 31928108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed or refractory myeloid malignancies.
    Kevlicius L; Cepulyte R; Vasilevska D; Griskevicius L; Zucenka A
    Bone Marrow Transplant; 2022 Jun; 57(6):1034-1037. PubMed ID: 35430592
    [No Abstract]   [Full Text] [Related]  

  • 9. Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.
    Soleimani A; Koka M; Singh ZN; Kesari V; Badros A
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e556-e559. PubMed ID: 32653454
    [No Abstract]   [Full Text] [Related]  

  • 10. Venetoclax in combination with carfilzomib, doxorubicin and dexamethasone restores responsiveness in an otherwise treatment-refractory multiple myeloma patient.
    Kovacs SB; Luan J; Dold SM; Weis A; Pantic M; Duyster J; Wäsch R; Engelhardt M
    Haematologica; 2020 Mar; 105(3):e138-e140. PubMed ID: 31467125
    [No Abstract]   [Full Text] [Related]  

  • 11. A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
    Gasparetto C; Bowles KM; Abdallah AO; Morris L; Mander G; Coppola S; Wang J; Ross JA; Bueno OF; Arriola E; Mateos MV
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):775-784. PubMed ID: 34551886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe Hypocalcemia Due to Skeletal Remineralization After Venetoclax, Bortezomib, and Dexamethasone for Relapsed Multiple Myeloma.
    Inglezou L; Tsekou G; Kotsianidis I; Spanoudakis E; Liapis K
    Ann Pharmacother; 2022 Sep; 56(9):1076-1078. PubMed ID: 34979809
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
    Kumar S; Kaufman JL; Gasparetto C; Mikhael J; Vij R; Pegourie B; Benboubker L; Facon T; Amiot M; Moreau P; Punnoose EA; Alzate S; Dunbar M; Xu T; Agarwal SK; Enschede SH; Leverson JD; Ross JA; Maciag PC; Verdugo M; Touzeau C
    Blood; 2017 Nov; 130(22):2401-2409. PubMed ID: 29018077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma cell leukaemia with t(11;14) not responsive to venetoclax.
    Abu Zaanona MI; Patel P
    BMJ Case Rep; 2021 Jan; 14(1):. PubMed ID: 33495184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
    Madero-Marroquin R; Dworkin E; Weiner H; Saygin C; Nawas MT; Drazer MW; DuVall AS; Kosuri S; Thirman MJ; Odenike O; Stock W; Larson RA; Patel AA
    Leuk Lymphoma; 2024 Jun; 65(6):864-867. PubMed ID: 38441062
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting Bcl-2 for the treatment of multiple myeloma.
    Touzeau C; Maciag P; Amiot M; Moreau P
    Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
    Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
    Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
    Shoumariyeh K; Jung J; Rassner M; Dold SM; Riebl V; Pantic M; Herget G; Marks R; Lübbert M; Wäsch R; Engelhardt M
    Ann Hematol; 2021 Jun; 100(6):1637-1640. PubMed ID: 33712868
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.